Saraf And Partners Acts For Viatris In Divestment Of Its Women’s Healthcare Business, And Active Pharmaceutical Ingredients (API) Business In India9 Oct 2023 9:54 PM IST
Saraf And Partners Acts For Viatris In Its Sale Of Biosimilars Business To Biocon Biologics For US$ 3.335 Billion1 Dec 2022 11:07 AM IST
